{"id":"tp-60796","type":"article-newspaper","title":"Health Canada Approves Lilly’s Mounjaro for Cardiovascular Risk Reduction","author":"Riza Dagoc","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/regulation/60796","datePublished":"2026-11-18T20:14:24.000Z","dateModified":"2026-11-18T20:14:24.000Z","language":"en","abstract":"The indication applies to adults with type 2 diabetes and established cardiovascular disease, with the decision based on SURPASS-CVOT trial results.","section":"Regulation","references":[]}